Novartis sees gene, cell therapy reaching up to 15pc of total revenue in midterm Medical Dialogues Bureau5 Sept 2019 9:15 AM ISTZURICH: Novartis sees cell and gene therapies accounting for up to 15% of its total revenue in the midterm from a much lower level at present, a Swiss...
Novartis, Gilead costly cancer therapies Yescarta, Kymriah losing patients to experimental treatments Medical Dialogues Bureau3 Aug 2019 9:15 AM ISTBoth Gilead's Yescarta and Novartis's Kymriah - which are part of a class of therapies known in the medical field as "CAR-T" - were approved in 2017....
Novartis Aimovig not cost effective: UK price watchdog Medical Dialogues Bureau11 Jan 2019 9:00 AM ISTNovartis, whose U.K. price for Aimovig is about 5,000 pounds ($6,374) annually but which was offering discounts, is counting on the medicine to be a...
Novartis to buy France's CellforCure to boost cell, gene therapy Medical Dialogues Bureau24 Dec 2018 9:00 AM ISTNovartis, which already has an agreement with CellforCure to help make Kymriah, said it aims to add CellforCure's facilities to a similar factory in...
Gene therapy for rare form of blindness wins US approval Ruby Khatun Khatun21 Dec 2017 10:04 AM ISTWASHINGTON: U.S. health officials on Tuesday approved the nation's first gene therapy for an inherited disease, a treatment that improves the sight of...
Novartis CAR-T therapy leads to durable response in lymphoma study Ruby Khatun Khatun11 Dec 2017 10:45 AM ISTPatients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy...
